Investor Presentation

November 03, 2026 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear Sir/Madam, Sub: Investor Presentation on Unaudited Financial Results for the quarter ended September 30, 2026. Dear Sir / Madam, Please find attached Investor Presentation on Unaudited Financial Results for the quarter ended September 30, 2026. The above information will also be made available on the website of the Company www.kopran.com Regards, For Kopran Limited Sunil Sodhani Company Secretary & Compliance Officer Membership No. FCS3897 Encl.: a/a. KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111 Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078. E-mail: cs@kopran.com Works:• Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337•Fax: (02192) 274025 CORPORATE PRESENTATION HY - 2026-27 This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be ‘forward-looking statements’, including those relating to the general business plans and strategy of Kopran, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks with respect to API and Formulation businesses. Kopran may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner. PERFORMANCE • Financial Highlights • Operational Performance • Formulation Q-2 Q-1 Q-2 HY HY FY PARTICULARS 2026-27 2026-27 2025-26 2026-27 2025-26 2025-26 Revenue from 21,126 15,399 11,791 36,526 25,313 68,142 Operations Forex Gain/Loss (219) 198 (824) (21) (585) (1,595) EBITDA* 1,822 1,588 299 3,410 1,709 7,825 Finance Costs 425 328 209 754 463 1,047 Depreciation 589 577 428 1,166 854 1,747 Tax Expenses 150 210 (170) 360 74 863 Net Profit 439 670 (992) 1,110 (247) 2,573 EBITDA Margin 8.62% 10.31% 2.53% 9.34% 6.83% 11.48% * EBIDTA excluding other income and forex losses APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX HY - 2026-27 Q2 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 360 214 61 743 51 1,766 54 1,931 1078 894 Anti- Diabetic Anti- Diabetic 3,308 Anti- Infective Antibiotic-Urological 1,344 Anti-Hypertensive 2 Anti-Hypertensive 2 Anti-Thrombotic 46 34 Anti-Thrombotic NSAIDs CNS Carbapenem Carbapenem Intermediate Intermediate Anti- Infective Macrolide Macrolide Anti-Urological Neuromodulator Neuromodulator NSAIDs 12,736 8249 Total Rs. 21,859 Lakhs Total Rs. 12,321 Lakhs APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX HY - 2026-27 Q2 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 3576 7437 Export Sales Export Sales Local Sales Local Sales 8745 14422 Total Rs. 21,859 Lakhs Total Rs. 12,321 Lakhs Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP HY - 2026-27 Q2 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 1970.00 1494 24.00 42.00 796.00 4054 Africa Africa CANADA Latem Middle East and North Africa Latem 25 South Africa 42 180.00 Middle East and North Southeast Asia Africa 227 South Africa 79.00 Canada Southeast Asia 8177 Total Rs. 14,131 Lakhs 5331.00 Total Rs. 8,422 Lakhs Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX HY - 2026-27 Q2 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 3744 6317 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 4678 7814 Total Rs. 14,131 Lakhs Total Rs. 8,422 Lakhs Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations Technology-focused and approvals by major global regulatory authorities. Company The formulations vertical is operated through Kopran Limited. Serving Regulated and The API vertical is being operated under Kopran Research Laboratories Ltd. Non-Regulated (KRLL), a wholly owned subsidiary of Kopran Limited Markets State-of-the-art Manufacturing Facilities * Our presence across two major verticals in the pharmaceutical value chain API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT ❖ Anti-hypertensive ❖ Development, manufacturing and ❖ Atenolol ❖ Macrolide sale of diverse APIs and Advanced ❖ Neuromodulator Intermediates ❖ Cephalosporins- Non-Sterile& Sterile ❖ Urological ❖ One ofthe leadersin Atenolol ❖ Macrolides ❖ Anti-infective/Anti-acne ❖ Sterile Carbapenem ❖ One of the major players in Sterile ❖ Granules ❖ Sterile Cephalosporin Carbapenems ❖ Anti-thrombotic ❖ SterileCarbapenems ❖ Intermediate ❖ World-class facility and quality ❖ Anti-Diabetic systems ❖ Multipurposeplants ❖ Cardiology ❖ NSAIDs ❖ Cateringexportanddomesticmarket ❖ Pilot plants ❖ Anti Lipid Located at 11,900 sq. mts. 26 FACILITY MIDC Mahad, Products commercialised built-up area Maharashtra FORMULATIONS FORMULATIONS VERTICAL PRODUCT SEGMENTS ❖ Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED ❖ Catering 100% export markets of both Regulated and Non-Regulated DOSAGE FORMS ORAL DOSAGE FORMS markets ❖ Manufacturers of more than 100 dosages meeting the standards of ❖ Anti-infective ❖ Macrolides international markets which includes Tablets, Capsules, Dry Powder and Suspension ❖ Amoxycillin ❖ Anti-hypertensive ❖ Ampicillin ❖ Cardiovascular DEDICATED FACILITIES ❖ Cloxacillin ❖ Anti-helmentics ❖ AmoxyClauv ❖ Anti-histamine ❖ Penicillin-based finished oral dosage forms ❖ EDS ❖ Non-Penicillin-based finished oral dosage forms ❖ Anti-diabetic ❖ CNS Located at ❖ Pain Management 11,432 sq. mts. FACILITY Khopoli, ❖ Gastroenterology built-up area Maharashtra STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP ❖ Focus on R&D to develop niche, ❖ Development of intermediates for APIs high-value/high-volume APIs and intermediates ❖ Reducing dependence on China to move towards self sufficiency ❖ Capacity expansion ❖ Optimising operational cost ❖ Compliance with Global Regulatory standards ❖ Process improvements: Improving yields of existing products ❖ Synergies between APIs and formulations ❖ Atomization of packing lines in formulations ❖ API and R&D facility at Panoli (Gujarat) BUSINESS DEVELOPMENT BALANCE PROFITABILITY & INVESTMENT FOR FUTURE ❖ Leveraging customer base for ne [Showing first 8,000 characters — download PDF for full document]